ICCCImmuCell Corporation

$60M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+11.2% YoY

Gross Profit

$3M41.6% margin

Operating Income

$1M13.9% margin

Net Income

$1M17.9% margin

EPS (Diluted)

$0.16

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$1M

Stock-Based Comp.

$52,215

Balance Sheet

Total Assets

$46M

Total Liabilities

$17M

Stockholders' Equity

$29M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$7M	+11.2%
Gross Profit	$3M	$2M	+46.1%
Operating Income	$1M	-$300,050	+472.5%
Net Income	$1M	-$437,868	+430.5%

Geographic Segments

UNITED STATES

$7M100%

ICCC Q1 2025 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena